M. Drouin

Most-cited papers

1. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.

   N. Isambert, M. Campone, E. Bourbouloux, M. Drouin +6 more

   2010European Journal of Cancer41 citations

   Semantic Scholar

   Save

2. Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors.

   N. Isambert, M. Campone, E. Bourbouloux, M. Drouin +5 more

   2006Journal of Clinical Oncology8 citations

   Semantic Scholar

   Save

3. Evaluation of the safety of C-1311 administered in a phase 1 dose-escalation trial as a 1-hour infusion once every 3 weeks in patients with advanced solid tumors.

   A. Thomas, A. Anthoney, S. Ahmed, M. Drouin +5 more

   2006Journal of Clinical Oncology4 citations

   Semantic Scholar

   Save

4. A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects

   M. Tanguay, Thomas Fröhlich, M. Drouin, G. Beuerle

   20182 citations Open access

   Semantic Scholar

   Save

5. A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects

   M. Tanguay, Thomas Fröhlich, M. Drouin, G. Beuerle

   2018AAPS Open0 citations Open access

   Semantic Scholar

   Save

6. Design of complement inhibitors that block IgG‐induced C3 activation through its properdin binding site

   E. Petitclerc, V. Mercier, M. Drouin, C. Simard +1 more

   20130 citations

   Semantic Scholar

   Save